Tag: Enveric Biosciences

Enveric Biosciences narrows net loss, advances lead drug candidate

Enveric Biosciences Inc. (NASDAQ: ENVB) reported its financial results for the third quarter of 2024 and provided a corporate update yesterday. Enveric said it made “important progress” in the development of EB-003, its lead neuroplastogenic molecule designed to treat depression, anxiety and addiction disorders without causing the hallucinogenic effects common to DMT and related analogs. According […]

Enveric inks $62M licensing deal for psilocin prodrug

Enveric Biosciences (NASDAQ: ENVB) agreed to license one of its experimental psychedelic drug candidates to MycoMedica Life Sciences in a deal worth as much as $62 million, as the biotech company keeps its eye on its non-hallucinogenic treatments. The agreement grants MycoMedica exclusive global rights to EB-002, a synthetic prodrug of psilocin, for treating neuropsychiatric […]